Cerus (NASDAQ:CERS) Upgraded by Zacks Research to Hold Rating

Cerus (NASDAQ:CERS) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

CERS has been the subject of a number of other reports. Wall Street Zen raised Cerus from a “hold” rating to a “buy” rating in a report on Saturday. BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cerus in a report on Wednesday, March 25th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Cerus in a report on Monday, January 12th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Cerus currently has a consensus rating of “Hold” and an average target price of $4.00.

Cerus Stock Performance

Shares of CERS stock opened at $2.72 on Thursday. The company has a current ratio of 1.73, a quick ratio of 1.17 and a debt-to-equity ratio of 0.62. The firm has a fifty day moving average price of $1.97 and a 200 day moving average price of $1.98. The company has a market cap of $545.01 million, a P/E ratio of -34.00 and a beta of 1.62. Cerus has a 12 month low of $1.15 and a 12 month high of $3.15.

Cerus (NASDAQ:CERS) last issued its earnings results on Thursday, April 30th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. The firm had revenue of $59.89 million during the quarter, compared to the consensus estimate of $55.68 million. Cerus had a negative net margin of 4.41% and a negative return on equity of 15.63%. Sell-side analysts predict that Cerus will post -0.05 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Vivek K. Jayaraman sold 165,200 shares of the stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $1.66, for a total value of $274,232.00. Following the completion of the sale, the chief operating officer directly owned 1,747,674 shares of the company’s stock, valued at approximately $2,901,138.84. This represents a 8.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Chrystal Jensen sold 30,845 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $2.01, for a total value of $61,998.45. Following the completion of the sale, the insider directly owned 1,059,139 shares of the company’s stock, valued at $2,128,869.39. The trade was a 2.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,194,282 shares of company stock valued at $2,106,290 over the last ninety days. Company insiders own 5.60% of the company’s stock.

Institutional Investors Weigh In On Cerus

Large investors have recently modified their holdings of the company. Cibc World Markets Corp acquired a new stake in shares of Cerus during the fourth quarter worth about $25,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Cerus during the third quarter worth about $31,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cerus during the first quarter worth about $32,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Cerus during the first quarter worth about $35,000. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Cerus during the third quarter worth about $35,000. 78.37% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Cerus

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Q1 results beat expectations: revenue rose ~22.6% YoY to $59.9M and diluted EPS was -$0.01, beating estimates — the top‑line beat and narrower loss are being cited as the primary catalyst lifting the stock. QuiverQuant: Q1 2026 Earnings
• Positive Sentiment: Analyst upgrade: BTIG Research raised CERS from “neutral” to “buy” with a $4.00 price target (material upside to the current level), which can attract momentum buyers and fresh coverage. The Fly / BTIG upgrade
• Positive Sentiment: Improving profitability & cash flow: operating loss narrowed substantially vs. last year, net loss fell sharply, and operating cash flow was positive ($6.2M); these trends reduce near‑term funding pressure. QuiverQuant: financial details
• Neutral Sentiment: Detailed context is available in the earnings call/transcripts for investors who want management color on growth drivers and timing. Seeking Alpha Transcript
• Neutral Sentiment: Small government contract receipts and mixed institutional flows: some large funds added positions while others reduced holdings — signals of both conviction and rotation into/out of the name. QuiverQuant: institutional & contract data
• Negative Sentiment: FY2026 revenue guidance was updated to $227.0M–$231.0M, which sits below consensus (~$233.9M) — the guide shortfall may cap upside if investors focus on FY outlook rather than the quarterly beat. MarketBeat: guidance note
• Negative Sentiment: Significant insider selling over recent months is a red flag for some investors and may weigh on sentiment despite improving results. QuiverQuant: insider trades

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.